+ progenitors and promyelocytes expressed these anti-apoptotic proteins. In AML, Bcl-2 expression was higher on CD34
Introduction
Programmed cell death (apoptosis) is controlled by an intrinsic genetic program remarkably conserved in evolution. All currently available cytotoxic drugs induce tumor death by triggering apoptosis, but many tumors have defects in the regulation of genes that control the programmed cell death process, thus rendering them resistant to chemotherapeutic agents. The members of the Bcl-2 family are critical regulators of the cell death pathway. 1 In gene transfection experiments, overexpression of Bcl-2 and its homolog Bcl-X L have been shown to render neoplastic cells resistant to induction of apoptosis by a variety of chemotherapeutic drugs. [2] [3] [4] [5] [6] Likewise, downregulation of Bcl-2 protein has been shown to reverse chemoresistance in several experimental systems. [7] [8] [9] [10] Chemosensitization has also been achieved by overexpression of proapoptotic proteins such as Bcl-X S and Bax. 11, 12 A schematic diagram of the apoptotic pathway is shown in Figure 1 . The assignment of pro-and anti-apoptotic function to particular Bcl-2 family members oversimplifies some of the complex alterations in this pathway: Bcl-2 can be cleaved by caspase 3 and becomes pro-apoptotic, and Bax can mutate and loose its death-promoting activity. 13 The mechanism by which Bcl-2 and Bcl-X L promote survival is not yet understood. Current data suggest the role of competitive dimerization between selective pairs of antagonists and agonists. Homodimerization of Bcl-2 and Bcl-X L results in strong anti-apoptotic function, while heterodimerization of the proapoptotic members Bax and BAD with Bcl-2 and Bcl-X L counteracts this function and shifts the balance towards apoptosis. 14, 15 Several recent experiments have indicated that post-translational modification of Bcl-2-related proteins can play an important regulatory role as well. Phosphorylation of Bcl-2 on serine residues appears to inhibit its anti-apoptotic function in some contexts. 16 In particular, the ability of chemotherapeutic agents that act on microtubules (eg taxol, vinblastine and vincristine) to induce phosphorylation of Bcl-2 during the G 2 -M phase has been implicated as a mechanism by which these anti-cancer drugs promote cell death. 16, 17 Conversely, serine phosphorylation of BAD reportedly disrupts its ability to bind to Bcl-X L , thus negating the proapoptotic function of BAD. 18, 19 In addition to dimerization with other Bcl-2 family members, Bcl-2 can bind to a p53-binding protein, p53-BP2, conceivably explaining how overexpression of Bcl-2 can interfere with the reported translocation of p53 from the cytosol into the nucleus in some types of cells. 20, 21 Furthermore, it has been demonstrated that Bcl-2 not only inhibits apoptosis but also restricts cell cycle entry [22] [23] [24] and that these two functions can be genetically dissociated. 25 This effect could provide additional cytoprotection, because proliferating cells are in general more vulnerable to apoptotic stimuli than nonproliferating cells.
It was recently reported that the most primitive hematopoietic precursors express Bcl-X L but not Bcl-2. 26 Bcl-2 is universally expressed in AML progenitors cells, and a subset of patients may have higher levels of expression than is found in normal CD34
+ cells. 27, 28 High levels of Bcl-2 protein have been reported to be of independent prognostic significance in AML. A high percentage of Bcl-2+ AML blasts correlated with failure to achieve complete remission (CR) and with shorter overall survival in one study. 29 Higher levels of Bcl-2 or higher ratios of Bcl-2:Bax have been reported to correlate with failure to achieve CR and with relapse by univariate analysis in other studies of adult AML. [30] [31] [32] Identifying strategies for overcoming the anti-apoptotic effects of Bcl-2 and Bcl-X L is a challenging goal of translational cancer research. Inhibition of Bcl-2 function might have a more pronounced effect on neoplastic than on normal cells for reasons related both to its anti-apoptotic and anti-cell proliferative functions. For example, since the loss of cell Pathways controlling apoptosis and necrosis. Activation of death receptors, DNA damage, growth factor loss, radio-or chemotherapy can result in activation of upstream caspases, activation of mitochondria, release of cytochrome c, activation of Apaf-1, subsequent activation of downstream caspases, and finally DNA fragmentation and apoptosis. The central role of anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-X L ) and of inhibitors like IAP (inhibitors of apoptosis proteins) is demonstrated. Mitochondrial activation resulting in release of Ca++, generation of free radicals, lipid peroxidation and ATP-depletion leads to necrosis (adapted from John Reed).
cycle control mechanisms in neoplasia drives cells into the cycle in spite of drug-induced damage, 33 tumor cells which lack the G 1 cell cycle checkpoint regulated by p53, might proceed into cycle in the absence of Bcl-2, thus putting themselves at risk for programmed cell death.
It has been reported that retinoids downregulate the expression of Bcl-2. We were therefore interested how ATRA would affect the chemosensitivity of AML cells, since this retinoid is commonly used in the treatment of acute promyelocytic leukemia. Antisense oligonucleotides (ODN) targeted against Bcl-2 have been employed to induce apoptosis of malignant cells or sensitize them to conventional chemotherapeutic drugs, [7] [8] [9] implying that retinoid-induced decreases in Bcl-2 ought to be similarly effective. The first clinical study of Bcl-2 antisense therapy in relapsed patients with relapsed and refractory non-Hodgkin lymphoma has recently been reported with encouraging results. 34 The activity of Bcl-2 was also selectively abrogated and drug-mediated cytotoxicity was enhanced by an intracellular anti-Bcl-2 single-chain antibody. 35 However, this approach necessitates delivery of antibody expression vectors into the target cells, making clinical applications for AML unlikely. Further elucidation of the molecular mechanisms of Bcl-2 function may therefore create the basis for the therapeutic correction of this disease-mediating dysfunction of cell death control.
We report here our results on studies of the expression of Bcl-2 family members in normal and leukemic hematopoietic progenitor cells, during induction chemotherapy, and in the minimal residual disease state. We also investigated the effects of retinoids on Bcl-2 expression and explored the cytotoxicity of retinoids in combination with Ara-C in AML cells in vitro.
Materials and methods

Cells
Bone marrow or peripheral blood cells for in vitro studies were obtained from patients newly diagnosed with AML or relapsed patients after obtaining informed consent according to institutional policy. The mononuclear cells were separated by Ficoll-Hypaque (Sigma Chemical, St Louis, MO, USA) density gradient centrifugation. The clinical features are listed in Table 1 . Morphological subtypes were determined according to FAB classification.
Normal bone marrow and G-CSF-mobilized progenitor cells from pheresis samples were separated by magnetic cell sorting (MACS). The pheresis samples were resuspended to 50 ml using cold RPMI medium and two 'soft-spins' were performed (centrifuge at 200 g for 10 min) to remove platelets. Bone marrow samples were Ficolled and washed twice. Cells were mixed with magnetic beads coated with anti-CD34 antibody (No. 467-01; Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's instructions, except that one half the recommended volumes of reagents were used. A MACS buffer consisting of Hank's buffered saline solution (HBSS) without calcium and magnesium (Cellgro Mediatech, Herndon, VA, USA), plus 0.6% ACD-A (Baxter, Deerfield, IL, USA), 0.5% BSA (Sigma) (pH 6.5) was used throughout staining and separation to prevent clumping of cells while maintaining optimal progenitor viability. Cells were separated on VS-positive selection columns (No. 413-06; Miltenyi Biotec) using a VarioMACS (Miltenyi Biotec) according to the manufacturer's instructions and as previously described. 36 The exception to these methods was that after washing, cells were backflushed to the top of the column outside of the magnet to increase purity rather than running the positive fraction over a second column. Cell purity was assessed by flow cytometry using CD34-PE and CD45-FITC as described by Sutherland et al 37 and was found to be Ͼ98%. Bcl-2 expression was determined by quantitative flow cytometry and expressed as ABC = antibody binding capacity/per cell. ABC total = ABC for the entire population, ABC CD34 = ABC of gated CD34 cells. Bcl-2 expression of CD34 AML cells is significantly higher than that of the entire population (for details, see text).
Flow cytometric analysis and cell sorting
Enterprise, Palo Alto, CA, USA) operated at 488 nm and 300 mW. Fluorescent signals were detected by 530/30 nm, 575/26 nm bandpass and 640 nm long pass filters. Cells were kept on ice during the sorting procedure and used subsequently for RT-PCR or fixed for FISH analysis.
Fluorescence in situ hybridization (FISH)
FISH analysis of FACS sorted cells was performed as described previously. 38 
RNA isolation and reverse transcription
RNA was isolated according to the single-step acid guanidinium thiocyanate-phenol-chloroform method. A reversetranscription kit was used to synthesize cDNA, according to the manufacturer's instructions (Boehringer-Mannheim, Indianapolis, IN, USA). One microgram of the total RNA template was used per 10 l of reverse transcriptase reaction. Primers for Bcl-2, Bcl-X, Bax and ␤ 2 -microglobulin were synthesized on an Applied Biosystems oligonucleotide synthesizer (Applied Biosystems, Foster City, CA, USA; Model 392). Onetenth of the RT reaction was used for each PCR reaction. The total volume of PCR is 25 l. Bcl-2, Bcl-X L , Bax and ␤ 2 -M cDNAs were amplified simultaneously in separate 0.2 ml MicroAmp tubes (Perkin Elmer, Foster City, CA, USA). The reaction conditions were as follows:
P-␣-dCTP, 1 × PCR reaction buffer (Perkin Elmer) and 1.5 U AmpliTaq DNA polymerase (Perkin Elmer). The thermal cycling was performed in a GeneAmp PCR system 9600 (Perkin Elmer) using the following parameters: 29 cycles of 94°C for 30 s, 63°C for 30 s, 72°C for 45 s, followed by a 10 min post-extension step at 72°C. Following thermal cycling, 3.0 l of the PCR produced was analyzed on an 8% polyacrylamide gel. Electrophoresis was performed for 3 h at 300 volts. The radioactive products were detected and quantitated on the Betascope-603 (Betagen, Waltham, MA, USA) for 30 min, followed by exposure on Kodak (Rochester, NY, USA) film at −70°C for 4-8 h without an intensifying screen. All experiments were performed in duplicate.
Immunoblotting
Cells were lysed in protein lysis buffer. Equal amounts of protein lysate were placed on 8% SDS-PAGE for 2 h at 100 volts followed by transfer of the protein on the Nytran membrane (S&S, Heween, NH, USA). Immunoblotting was performed at room temperature for 2 h with 5% milk, incubated with the first antibody in 1:1000 dilution for another 2 h, followed by three washes in PBS. The procedure was repeated for the secondary antibody followed by soaking the blot in ECL buffer for 1 min and then exposing it to the ECL films. The antibodies to BCL-X L and Bax were used at 1:1000 dilution. 39, 40 Immunoblotting for BAD was carried out as follows: the protein from the lysed cell was loaded on 12% SDS-PAGE gel. Then, the protein was transferred to the nitrocellulose membrane. The blot was blocked in 5% milk overnight, and then incubated with specific BAD and BAD phosphorylation (S-112 and S-136) antibodies (BioLabs, Beverly, MA, USA). The secondary antibody was used for 1 h, followed by three washes with TBS buffer. ECL plus was used for signal detection.
Detection of Bcl-2 protein by flow cytometry
AML blast cells were first stained with PE or PerCP-conjugated anti-CD34 monoclonal antibody (Becton Dickinson) and used at 1/10 dilution. Staining procedure was performed as described elsewhere. Cells were fixed in 1% formaldehyde (Sigma) and permeabilized with 10% Triton X in PBA (1% albumin, 0.1% NaN3) for 10 min at 4°C. The cells were washed twice in PBS. Appropriate PE or PerCP-conjugated lgG 1 -stained cells were incubated for 15 min at 4°C with 10 l of FITC-conjugated mouse IgG 1 control antibody (DAKO, Carpinteria, CA, USA). All assays were performed with a single lot of FITC-conjugated antibody, therefore samples were analyzed with the same coupling ratio of FITC/antibody. Cells stained with CD34-PE or PerCP antibody were incubated with 10 l of FITC-conjugated monoclonal mouse anti-human bcl-2 protein (DAKO bcl-2) lgG 1 . The cells were washed in PBS and analyzed immediately using the FACSCAN flow cytometer equipped with an argon (488 nm) laser and Lysys software (Becton Dickinson). Appropriate single-color stained cells were used for compensation control. for each sample, at least 10 000 cells were analyzed; cells were live-gated according to CD34-and/or Bcl-2-positivity, and the mean channel number was used for comparison of Bcl-2 expression by AML blasts (Figure 2 ). The relative channel number (RCN) was measured from the upper limit of the negative control. The relative channel number of a series of calibrated FITC microbeads having levels of fluorescence intensity ranging from 8.9 × 10 3 to 206.1 × 10 3 antibody-binding capacity (ABC) of equivalent soluble fluorochrome per bead was calculated (FCSC Quantum; Becton Dickinson) and a standard curve constructed. The RCN and the number of ABC per cell for the test samples were calculated using this standard curve.
Apoptosis
Apoptotic cells were detected by a DNA fragmentation assay using ApoTag Plus detection kit (Oncor, Gaithersburg, MD, USA) as recommended by the manufacturer. Briefly, sorted cells were fixed in 1% paraformaldehyde. After washing and applying equilibration buffer, the cells were incubated with TdT in a humidified chamber at 37°C for 1 h. After washing, cells were stained with anti-digoxigenin-fluorescein for 30 min at room temperature. Thereafter, slides were washed, counterstained with DAPI and viewed by Nikon UFX-II fluorescence microscope. For negative control, water was mixed instead of TdT enzyme into the reaction buffer. A positive control slide was prepared from peripheral blood lymphocytes treated with 1 M dexamethasone for 4 h.
Statistical analysis
All results are reported, where applicable, as the mean ± standard error of mean (s.e.m.). Statistical analysis between paired data was performed using the paired Student's t-test. Generalized linear model was used for analyzing the repeated measurements of Bcl-2.
Results
Expression of Bcl-2 in myeloid leukemic cells and their progenitors
As shown in Table 1 , 27 samples were analyzed by quantitative flow cytometry for Bcl-2 expression within all cells (ABC total) and within CD34
+ cells (ABC CD34). The correlations between Bcl-2 mRNA detected by RT-PCR, and protein determination by either immunoblot or quantitative flow cytometry (FCM) are shown in Figure 3 . In AML, the FCM Bcl-2 values ranged from 2107 to 146 006 ABC/cell. The lowest value recorded was 719 ABC using cells from a patient with CMML. In all cases (except patient No. 3 in Table 1 ), CD34 cells expressed higher levels of Bcl-2 as compared to the total population (P = 0.000061). This was true for patients who achieved CR (P = 0.019) and who failed to achieve CR (P = 0.002). In Table 2 , results are analyzed with regard to achievement of CR vs failure to achieve CR. There was no significant difference in Bcl-2 expression either when measured in all cells (P = 0.57) or in CD34 cells between the CR and non-CR groups (P = 0.60), suggesting that Bcl-2 expression prior to treatment did not predict for response to induction chemotherapy. No apparent correlation was found between Bcl-2 expression and FAB classification or cytogenetic group, within the limitations of this sample size.
Expression of Bcl-2 family members in AML
Bcl-2 family members with pro-apoptotic (Bax, Bcl-X S , Bak, Bad) and anti-apoptotic (Bcl-2, Bcl-X L , MCL-1) function were analyzed in newly diagnosed AML (n = 48). Figure 4 (upper panel) shows the comparison between RT-PCR for Bax, Bcl-2, Bcl-X L , Bcl-X S (left) and immunoblot analysis (right) of the same samples. In general, there was good correlation, although the anti-Bcl-X antibody used did not detect Bcl-X S , which was expressed at very low levels as determined by RT-PCR, and some discrepancies in the mRNA and protein levels were apparent (eg lanes 1 and 7) . This suggests that the Bcl-X S protein may be unstable or its levels regulated by posttranslational mechanisms. Figure 4 (lower panel) shows Bcl-2, Bcl-X L , and Bax levels, as determined by immunoblotting in all 48 patients studied. Bcl-2 was expressed in essentially all samples, although at different levels, which was consistent with the results obtained by quantitative flow cytometry. Bcl-X L was likewise expressed in essentially all samples. Bax was also expressed at different levels in all samples. The control cell line, MO7e, had low levels of Bcl-2 but high Bcl-X L expression. In this series, no correlation between the expression of these Bcl-2 family members and FAB classi- fication, sex, cytogenetic group, age, or achievement of CR was found for patients receiving Ara-C/anthracycline-based therapy.
Univariate and Cox regression analysis identified high Bcl-2 expression in association with better overall survival (P = 0.04), after cytogenetics and achievement of CR. These results were corroborated in a separate group of patients with unfavorable cytogenetics (n = 87): in this series, low Bcl-2 levels were associated with shorter survival (P = 0.003). 41 This unexpected result raised the question whether Bcl-2 in AML is inactivated by phosphorylation. In a series of 20 AML samples, no evidence of Bcl-2 phosphorylation was detected by immunoblot analysis, where slower migration of Bcl-2 protein is the expected result (C Croce, M Andreeff, personal communication).
Expression of BAD was found in 84% of AML (Figure 5a ). In 41/42 samples analyzed, the BAD protein migrated as a doublet, indicating the presence of phosphorylated BAD. Table 1 ).
Phosphorylation of BAD is known to inactivate this proapoptotic gene and this finding suggests widespread phosphorylation of BAD protein in AML, although to varying degrees. We then examined the phosphorylation sites of BAD, using antibodies specific for phosphorylated serine 112 and serine 136 (Figure 5b ). In 10/11 AML, SER 136 and in 11/11 SER 112 was phosphorylated, confirming the results shown in Figure 5a . Figure 6 , Bcl-X L was highly expressed in the earliest compartment CD34
Expression of Bcl-2, Bcl-X L , Bcl-X S and Bax in normal hematopoietic progenitor cells
− and to Table 3 . The interesting finding here is that both anti-apoptotic genes, Bcl-2 and Bcl-X L are expressed in the majority of CD34 cells, but that the most immature compartment lacks expression of Bcl-2, while Bcl-X L is highly expressed. When cells leave the CD34 compartment and develop into promyelocytes (CD34 − /33 + ), they loose both Bcl-2, Bcl-X L and Bax. Leukemic and normal promyelocytes are compared in Table 4 which shows the absence of Bcl-2, Bcl-X L and Bax expression in normal, as compared to the high expression of Bcl-2 and Bcl-X L in leukemic promyelocytes. As shown in Figure 5a , BAD is expressed in normal CD34 cells, in both phosphorylated and unphosphorylated forms; its expression in normal promyelocytes has not been studied.
Changes of Bcl-2 expression of AML progenitor cells during induction therapy
After having failed to demonstrate a prognostic importance of Bcl-2 for achievement of CR in bulk AML cells and in CD34 + AML progenitors, we examined changes of Bcl-2 levels during induction chemotherapy of patients with AML. Twenty-five patients were investigated at baseline, and on days 1, 2, 3, 4 of Ara-C and idarubicin-based induction chemotherapy. Seventeen patients (65%) achieved complete remission, four were resistant, and four failed to achieve CR for other reasons (Table 5) . Their CD34 Bcl-2 baseline levels varied but did not predict for achievement of CR (P = 0.28). However, increasing Bcl-2 levels in CD34 cells were observed during subsequent days of chemotherapy. The increase can be described by the equation: y = 8.74 + 0.74 x day − 1.8F x F − 1.45 x R, where y is the square root of Bcl-2 mean channel fluorescence, x are days of therapy, and F = 1, CR = 0, R = 1. Figure 7 shows the 
13
+ cells were FACS sorted from patients in CR with minimal residual disease (MRD) and exhibited high levels of both, Bcl-2 and Bcl-X L mRNA. CD34
−
33
+ leukemic promyelocytes, express both anti-apoptotic genes. Results were obtained by RT-PCR as shown in Figure 6 .
Table 4
Leukemic promyelocytes express high levels of Bcl-2 and
Bcl-2 and Bcl-X L mRNAs were not detectable by RT-PCR in normal promyelocytes.
Bcl-2 increase over time for the three groups of patients. This effect was highly significant (P = 0.004) and did not differ between patients who subsequently achieved CR, failed or were classified as resistant to chemotherapy. This finding allows two interpretations: either chemotherapy increases Bcl-2 expression levels in AML cells, or chemotherapy eliminates progenitors with low Bcl-2 expression suggesting that increased Bcl-2 levels confer survival advantage. Sequential flow cytometric studies of CD34/Bcl-2 suggest that the latter explanation is correct, without eliminating the first one: as shown in Figure 8 , the pretreatment Bcl-2 content of CD34 cells was intermediate (day 0). Only 210/10 000 cells expressed high levels of Bcl-2 (right upper quadrant). On day 2 of induction chemotherapy, when the circulating WBC had decreased from 80 × 10 6 cells/ml to 0.8 × 10 6 /ml, a population of CD34 + cells expressing high levels of Bcl-2 was detected. The relative frequency of these cells had increased from 2% to 25%. 'Lifegating' of these cells in the pretreatment sample clearly identified them as preexisting, at a frequency of 1527/100 000. Induction chemotherapy therefore eliminated cells with lower Bcl-2 content and spared CD34 cells with very high Bcl-2 content.
Bcl-2 and Bcl-X L are overexpressed in minimal residual disease in AML
If Bcl-2 and Bcl-X L confer survival advantage during induction chemotherapy, it might be possible that residual leukemic Twenty-five patients with AML were followed before (day 0) and on days 1, 2, 3 and 4 of induction chemotherapy. CR, complete remission; resistant, resistant AML; fail, failure to achieve CR. Status: D, dead; A, alive. EFS, event-free survival (months); survival, survival from diagnosis (months). D0, pretreatment expression of Bcl-2 on CD34 cells (×10 3 ABC/cell), D1, 2, 3, 4, days 1-4 of chemotherapy.
cells, in patients in CR, share these molecular characteristics. We therefore FACS-sorted cells expressing the abnormal CD34 + /13 + phenotype in four patients in CR with known monosomies of chromosome 7. The normal compartment CD34 + 13 − was also FACS-sorted and samples were subjected to RT-PCR and FISH analysis. FISH demonstrated the presence of over 50% of cells with monosomy 7 in the CD34 + 13 + but not in the CD34 + 13 − population. 38 RT-PCR showed high levels of Bcl-2 (not shown) and Bcl-X L mRNA ( Figure 9 ) in minimal residual disease, but not in the normal cells. Of note are also the altered Bcl-X L /X S ratios in samples at diagnosis and at relapse: the anti-apoptotic Bcl-X L /X S ratio was increased in minimal residual leukemic cells compared to newly diagnosed AML.
Flow cytometric analysis of CD34, CD13, and Bcl-2 identified these cells in one patient: a population of CD34 + /CD13 
ATRA downregulates Bcl-2 mRNA and protein in leukemic cells and enhances the cytotoxic effect of Ara-C
We then examined the effect of all-trans retinoic acid (ATRA) on HL-60 leukemic cells, alone and in combination with Ara-C ( Table 6 ). The ATRA concentration used was 10 −6 M, as was the concentration of Ara-C. In these experiments, we also altered the sequence of ATRA and Ara-C, giving ATRA first followed by Ara-C and vice versa. Ara-C or ATRA or saline was added to exponentially growing HL60 cells at time 0. After 48 h, the drugs were washed out and cells were subsequently exposed to ATRA, Ara-C or RPMI medium. Bcl-2 mRNA levels were determined at 1, 2, 4, 8, 24 and 48 h after Ara-C or ATRA (right lower panel), Bcl-2 protein levels were measured by quantitative flow cytometry at 24 and 48 h following Ara-C or ATRA, and again at 24 and 48 h following washout and ATRA, RPMI, or Ara-C (right upper panel). The number of apoptotic cells was determined at these timepoints (left lower panel) as was the number of clonogenic cells, calculated as the number of colonies/6 × 10 4 cells (left upper panel). All experiments were carried out in duplicates or triplicates. Results are shown as means.
As shown in Table 6 , control conditions at 48 or 96 h had no effect on the number of apoptotic (3.3-4.8%) or clonogenic (565-515 colonies) cells. Bcl-2 mRNA levels decreased at 2 and 4 h after Ara-C to 70.7%±, but recovered to baseline levels at 24 and 48 h. ATRA induced downregulation of Bcl-2 mRNA within 2 h to ෂ45% of control, with sustained decreases at 24 and 48 h. Bcl-2 protein levels after ATRA treatment decreased to 76.3% at 48 h and to 55.4% at 72 h, with subsequent recovery at 96 h. ATRA followed by Ara-C had no additional effect on Bcl-2 protein levels. However, Ara-C followed by ATRA resulted in a sustained Ͼ50% decrease in Bcl-2. The number of apoptotic cells was likewise highest for Ara-C followed by ATRA (25.6%), more than twice as high as those found when ATRA was followed by Ara-C (10.7%). Moreover, clonogenic assays also demonstrated that Ara-C followed by ATRA reduced the number of colonyforming units to 16% (91 colonies) of control at 96 h while ATRA followed by Ara-C reduced colony counts only to 40% (221 colonies) of controls.
These results suggest that the sequence of Ara-C followed by ATRA exerts a maximum effect on Bcl-2 protein levels, reduction in clonogenic survival, and induction of apoptosis, while ATRA followed by ARA-C was less than half as effective.
Figure 7
Change in Bcl-2 expression of CD34 cells during induction chemotherapy of AML. Y axis: square root of Bcl-2 mean channel fluorescence, X axis: days. Day 0, pretreatment; days 1-4, days on chemotherapy. Results are shown for patients who achieved CR, failed to achieve CR or were classified as resistant. There was a significant increase in Bcl-2 expression of CD34 + cells from pretreatment values to day 4 (P = 0.004).
Discussion
Proteins structurally related to Bcl-2 form a complex network that regulates important steps leading to or preventing apoptosis. Dysregulation may contribute to the accumulation of malignant cells, but also to the resistance of malignancies to therapeutic interventions. Hence, we attempted to better understand the role of these molecules in myeloid leukemia.
When we determined Bcl-2 expression in newly diagnosed AML cells, a very large variation in expression was observed. Selective determination of Bcl-2 expression in CD34 + cells revealed significantly higher expression in leukemic CD34 cells than in the entire leukemic population. This finding follows the paradigm of normal hematopoiesis, where Bcl-2 expression is maximal in CD34 cells, followed by downregulation as cells differentiate. We did not find gross evidence of phosphorylation of Bcl-2 in newly diagnosed AML. Surprisingly, no difference in Bcl-2 expression was found between patients who achieved CR and those who failed to do so. This finding suggests that other factors may be better determinants of chemosensitivity or resistance, but does not preclude a role for Bcl-2 in drug resistance, given the overall poor outcome of AML therapy.
The development of multiparametric flow cytometric assays to determine Bcl-2 on selected progenitor cell populations opened opportunities for studying very small stem cell populations, which are not amenable to Western blot analysis. Our findings confirm those by Park et al, 26 and show that normal CD34
This finding is of potential importance with respect to attempts to employ Bcl-2 antisense oligonucleotides therapeutically and suggests that the most primitive hematopoietic stem cells would be spared. Once cells leave the CD34 + compartment and differentiate to promyelocytes (CD34 − /33 + ), Bcl-2 and Bcl-X L are both downregulated in normal, but not in leukemic cells, thus providing a potential differential target.
The finding that high Bcl-2 expression was associated with good survival was surprising. However, this was confirmed in a second series by Kornblau et al 41 and appears related to the cytogenetic subgroup investigated: in patients with 'good prognosis' cytogenetics, low Bcl-2 levels were associated with good prognosis, while in poor prognosis cytogenetics, the reverse was found. Our data do not elucidate this finding. Possibly, other regulators of apoptosis are selectively expressed in patients with 'poor prognosis' cytogenetics and disrupt the canonical apoptotic pathway that is operational in patients with 'good prognosis' cytogenetics. The human CED-4 homologue Apaf-1, 42 which participates in cytochrome cdependent activation of caspase 3 (Figure 1) , was found by us to be expressed in 58% of AML 43 and will be examined in this context. An alternative explanation for the 'paradoxical' role of Bcl-2 in poor prognosis AML could be the antiproliferative effect of Bcl-2: leukemias with high Bcl-2 levels would have slower repopulation kinetics, which would result in longer survival. This hypothesis also remains to be tested.
Results presented here for BAD show expression in almost all samples studied. Importantly, BAD is phosphorylated on Ser 112 and Ser 136 in essentially all samples studied. BlumeJensen et al 44 demonstrated that P13-kinase and Akt-mediated phosphorylation of BAD on Ser 136 by cytokine receptor pro- 
13
+ cells was determined by FISH, which showed monosomy of chromosome 7 in the CD34 +
+ population.
Table 6
Effect of ATRA and Ara-C on HL-60 cells
Clonogenic assays, induction of apoptosis, and effects on Bcl-2 protein and Bcl-2 mRNA are shown. The sequence: Ara-C followed by ATRA results in the most significant downregulation of Bcl-2 protein, reduction of clonogenic cells and induction of apoptosis (for details, see text). Results shown are from experiments conducted in duplicates or triplicates and are expressed as means.
moted cell survival. Hence, BAD phosphorylation could result in inactivation of the pro-apoptotic function of BAD. Mechanistic studies to evaluate this hypothesis and to identify the relevant kinases are underway. When patients were monitored during induction therapy, a significant increase in Bcl-2 expression of leukemic CD34 cells was noted. This change was consistent, regardless of the patient's response to therapy. This could either indicate induction of Bcl-2 by chemotherapy, or selection of Bcl-2-overexpressing cells during therapy. Serial studies in a small number of patients indicate that cells with very high Bcl-2 content are pre-existing, and have a survival advantage during the first days of chemotherapy. Therefore, downregulation of Bcl-2 would be potentially advantageous. The putative cytoprotective function of Bcl-2 and Bcl-X L is further substantiated by the finding of expression of Bcl-X L and Bcl-2 in minimal residual leukemic cells in patients in remission. Again, these antiapoptotic genes could be potential therapeutic targets in AML in remission and antisense oligonucleotides directed against the translocation initiation site of Bcl-2 have been used by us to induce apoptosis in AML progenitor cells. 45 ATRA was found to downregulate Bcl-2 mRNA in HL-60 cells, with subsequent declines in Bcl-2 protein levels and apoptosis. 46 ,47 Therefore, we tested the hypothesis that ATRA in combination with Ara-C would increase the efficacy of Ara-C therapy in vitro. Interestingly, there was no enhancement of Ara-C toxicity when ATRA preceded Ara-C. However, significant reductions in Bcl-2 protein levels, decreases in clonogenic survival and increases in induction of apoptosis were seen in vitro, when ATRA was given after Ara-C. The combination of Ara-C and ATRA (with and without G-CSF) has been tested in a large clinical trial and initial results indicated that ATRA + G-CSF increased survival of patients with AML. 48 In that trial, ATRA was given before, during and after chemotherapy consisting of fludarabine, Ara-C and idarubicin. However, the final analysis of 215 patients demonstrated no beneficial effect of ATRA (+G-CSF) on CR rate, survival or event-free survival in poor prognosis AML or high-risk MDS. 49 This could be due to the non-canonical role of Bcl-2 in poor prognosis AML, ie high levels of Bcl-2 conferring relatively good prognosis and downregulation by ATRA may be detrimental, or to the suboptimal sequence of ATRA preceding chemotherapy. The results presented here, if confirmed in samples from primary AML, suggest that clinical trials should be conducted in which ATRA follows chemotherapy in patients who could potentially benefit from the transcriptional down-regulation of this anti-apoptotic protein.
